Mechanistic Immuno Tox Scientist — Roche

Full description

At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections, where you are valued, accepted and respected for who you are, allowing you to thrive both personally and professionally. This is how we aim to prevent, stop and cure diseases and ensure everyone has access to healthcare today and for generations to come. Join Roche, where every voice matters.

The Position In Roche’s Pharmaceutical Research and Early Development organisation (pRED), we make transformative medicines for patients to tackle some of the world’s toughest unmet healthcare needs. At pRED, we are united by our mission to transform science into medicines. Together, we create a culture defined by curiosity, responsibility, and humility, where our talented people are empowered and inspired to bring forward extraordinary, life-changing innovation at speed.

At the intersection of science and innovation, pRED’s Pharmaceutical Sciences (PS) organisation enables the discovery and development of safe and effective therapeutics at optimal doses in relevant populations with a vision to power translation, continuously improve the accuracy of our predictions and accelerate the development of tomorrow's medicines. By seamlessly integrating our three core pillars—Translational Safety, Translational Pharmacology, and Biomarkers - we drive end-to-end asset development across the entire value chain, from target assessment to on-market support. Our mission is to continuously improve predictive accuracy, optimise dosing strategies for the right patient populations, and accelerate the development of tomorrow's safe and effective therapeutics.

This position is located in Pathology and Applied Safety Science, a department within the Pharmaceutical Sciences function. We drive the non-clinical safety assessment of drug candidates from small molecules to complex biological products during the discovery and development phases at Roche.

The Opportunity

• In Vivo - in vitro Immunosafety Integration & Mechanistic Strategy: Formulate, implement, and champion integrated immunosafety strategies for portfolio projects, ensuring the scientific validation and execution of predictive immunological biomarkers. Interrogate and decode in vivo immunosafety findings (e.g., changes in lymphoid architecture, immunogenicity readouts, cytokine profiles, or systemic hypersensitivities) and connect them back to mechanistic context using investigative in vitro tools. Translate complex immunological findings into unified safety position documentation, presenting definitive impact summaries for target validation, compound profiling, and IND/CTA-enabling packages.
• Advancing In Vitro Cellular Models via Immunological Elements: Proactively apply human immunology elements (e.g., primary immune cells, immune-epithelial co-cultures, inflammatory stimulus circuits) to upgrade the physiological accuracy of predictive in vitro cell models. Pioneer the optimisation, validation, and scale of 2D, 3D, and fluidic microphysiological safety systems, ensuring that models capture intricate human-specific responses like cytokine release syndromes, immune-mediated organ toxicities, or structural hypersensitivities. Drive proficiency in state-of-the-art analytical platforms such as high-content screening, flow cytometry, multiplexed fluid assays, and spatial or transcriptomic single-cell readouts.
• Proactive Data Curation, Reporting, & LIMS Operations: Conduct rigorous data analysis, critical validation of assays, and proper internal reporting of study phase data within the Laboratory Information Management System (LIMS). Act as the lead presenter of immunotoxicology assessments, translating highly specialised immune data into actionable, easy-to-digest go/no-go recommendations for project toxicologists and multi-disciplinary teams. Ensure impeccable documentation, maintain pristine raw data storage folders, and st